- Mark Cuban warned the cost and drugs could increase prices due to potential rates.
- The pharmacy cannot absorb the impact of a high price on medicines imported from India, said Cuban.
- The American trade negotiations of India continue while the two nations seek an agreement in the midst of pricing tensions.
Cost Drugs buyers could feel the effects of future prices in their wallets.
Although the pharmaceutical company is sheltered from President Donald Trump’s prices on China, the co -founder Mark Cuban said that any potential price on goods imported from India would force costs plus drugs to increase the price of its drugs.
“We will not have the choice,” said Cuban during an appearance on the podcast “someone Gotta with Tara Palmeri”.
Cuban founded Cost Plus Drugs in 2022 as an online drug distributor at a reduced price which aimed to be transparent with consumers on prices and removed the middle of the pharmaceutical system. He was frank in his criticism of the Trump administration policies.
If the prices of India were implemented, he said, his business would be transparent with consumers on the cost of prices and broker costs and would transmit them “directly” to customers. There would be no way for costs and medications to “eat” costs.
Trump has already described India as “tariff king” and, more recently, said that he planned to implement reciprocal prices on countries that charge American products. Last week, officials from the United States and India met to discuss trade issues.
The average rate rate in the United States is approximately 2.2%, compared to the average of 12% of India in 2023, according to data from the World Trade Organization cited by Reuters.
Offering drugs at the lowest possible price is part of the mission of the Cuban online pharmacy. In the current state of things, consumers pay an increase of 15%, more costs of $ 5 for the workforce on each medication and $ 5 for shipping.
“If you only have a 15% markup and there is a price of 25%, we have to lose money on each medication,” said Cuban.
businessinsider